IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE: IOT), a pioneer in the field of biofilm product development, today announced that it has received its first purchase order for InnovoSCEPT™ veterinary biofilm susceptibility tests for launch into the Japanese veterinary market. The Company anticipates expansion to the balance of the worldwide veterinary market to follow quickly.

"This initial order of InnovoSCEPT™ veterinary tests provides a new and improved method to identify effective treatments for chronic infections in animals. The situation in the animal world parallels what is seen in human health, where inappropriate treatment of chronic infections results in unnecessary patient suffering, repeated treatment failures, increased health care costs and an increase in the potential for bacterial resistance," said Ken Boutilier, President and CEO of Innovotech. "Our company has developed the InnovoSCEPT™ line of five new products for susceptibility testing in both humans and animals in less than six months. This initial purchase order for introduction into the Japanese market is just the start of what should become an important revenue generator."

The InnovoSCEPT™ line of veterinary tests, based on the technology used to develop Innovotech's bioFILM PA™ human susceptibility test, will assist veterinarians in the selection of the most effective antibiotic treatment of infections caused by both gram-positive and gram-negative bacteria in both small and large animals. As with human infections, many common disease-causing bacteria exist in animals as biofilms, such as those responsible for infections causing mastitis in dairy cows or persistent skin infections in family pets. These chronic infections are often difficult to eradicate and Innovotech's tests have a much better chance of being successful in the identification of the best treatment approach in comparison to current methods.

Biofilms are organized communities of microorganisms that exist in virtually every natural environment. Biofilms can be up to 1000 times more resistant to treatment than the same organism in a free-floating state.

About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are responsible for a host of diseases both in human health and agriculture due to their inherent resistance to existing antibiotics and disinfectants. Aside from Innovotech's products there are no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically for biofilm-forming organisms.

Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including three commercial products, the MBEC Assay™, bioFILM PA™ and InnovoSCEPT™ veterinary kits. The MBEC Assay™ is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA™ is the first diagnostic kit to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections, while the InnovoSCEPT™ veterinary kits are designed to determine the most effective antibiotic treatment for infections in both large and small animals.

Innovotech also has two products in advanced stages of development; Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections and Sani-Lux™ is a light-activated, natural hard surface sanitizer.

Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter:www.twitter.com/innovotech

Facebook:www.facebook.com/innovotech

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contacts: Innovotech Inc. Ken Boutilier President and CEO (780) 448-0585 ext. 221 (780) 424-0941 (FAX) ken.boutilier@innovotech.ca Innovotech Inc. Amanda Stadel Communications Officer (780) 448-0585 ext. 224 (780) 424-0941 (FAX) amanda.stadel@innovotech.ca www.innovotech.ca